Business Wire

Bacardi Expands Its TAILS® COCKTAILS PROFESSIONAL Range: New Look, New Cocktails, Same Premium Quality

Share

Bacardi, the largest privately held spirits company in the world, has expanded its pioneering TAILS® COCKTAILS PROFESSIONAL range with new cocktails and a new look, available now for the hospitality industry across Western Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005150/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BACARDI EXPANDS ITS TAILS® COCKTAILS PROFESSIONAL RANGE ACROSS WESTERN EUROPE (Photo: Business Wire)

The premium batched cocktail brand offers the on-trade a hassle-free solution for serving quality cocktails easily, quickly and consistently at scale. Serving a TAILS cocktail takes as little as 15 seconds, and no specialist training is required.

The expanded range of classic and contemporary cocktails, all crafted using the Bacardi portfolio of premium brands has two new additions; the Whisky Sour, made with DEWAR’S® Blended Scotch whisky; and the Rum Punch, made with BACARDĺ® rum.

“Thousands of outlets across Europe are already enjoying a new revenue stream by serving TAILS COCKTAILS PROFESSIONAL, and this year we’re planning to more than double that number – the momentum is huge,” says Evert-Jan Bos, General Manager, TAILS COCKTAILS.

He adds: “With the new flavors, we’re catering for even more tastes and occasions – from summer terraces to cosy winter bars – offering an exciting opportunity for the hospitality industry to tap into the growing demand for cocktails.”

The expanded range also includes the Passion Fruit Martini Cocktail and Espresso Martini Cocktail, both made with 42BELOW® vodka; the Gin Garden Cocktail made with BOMBAY® Dry gin and ST-GERMAIN® elderflower liqueur; and the Classic Mojito and Berry Mojito, both made with BACARDĺ rum.

As well as the new-look 1L bottles, there are also three TAILS COCKTAILS PROFESSIONAL 20L kegs - the Passion Fruit Spritz made with 42BELOW® vodka, and the Classic Mojito and Caribbean Punch, both made with BACARDÍ rum – rolling out this summer, allowing outlets to serve cocktails on draught for even quicker, easier service.

With a full live music and events line-up back in Europe this year, Bacardi will also bring high quality cocktails to festivals at scale, with TAILS COCKTAILS PROFESSIONAL at more than 20 of the biggest festivals across the UK, Spain, Belgium and the Netherlands.

The range sits alongside the company’s recent launch of TAILS COCKTAILS, which takes TAILS into the off-trade for the first time, pioneering a new ‘ready-to-shake’ category within cocktails-at-home.

For more information, visit www.tailscocktails.com/professional.

Always drink responsibly

About the TAILS® COCKTAILS PROFESSIONAL range

TAILS COCKTAILS crafts expertly batched cocktails to ensure consistent quality and speed of service throughout the hospitality and events industry. Established in 2010, TAILS COCKTAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS cocktail begins with the highest quality, premium spirits – BACARDI® rum, 42BELOW® vodka, BOMBAY SAPPHIRE® gin, DEWAR’S® Blended Scotch whisky and ST-GERMAIN® elderflower liqueur – blended with top quality ingredients. The range is available in both 1L bottles and 20L kegs with draught pillars. The TAILS COCKTAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Visit www.tailscocktails.com/professional.

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY® Dry gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Phillippa Williams, Corporate Communications Manager, Western Europe, Australia & New Zealand, pholmes@bacardi.com
Andrew Carney, Corporate Communications Director, Western Europe, Australia & New Zealand, acarney@bacardi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye